Comments
Wockhardt has set up its first facility in West Asia for the manufacture of new chemical entities (NCEs) to cater to global markets.
The facility is spread over 10,000 sq meters, self-sufficient for handling warehousing, manufacturing operations, product testing and product stability, Wockhardt said in a statement today.
“With the new facility in the Middle East, we aim to focus on our commitment to developing NCEs to fight the health issues,” Wockhardt Founder Chairman Habil Khorakiwala said.
He added that Wockhardt is poised for a quantum leap into the future. The company however did not provide any details about the investments it has made for setting up the facility.
“With Wockhardt’s commitment to research and development, we have 5 breakthrough NCEs that have been accorded Qualified Infectious Disease Product (QIDP) status by USFDA,” Khorakiwala said.
The five novel antibiotic drugs are in advanced stage of global clinical development.
“Wockhardt has dedicated significant resources for the discovery and development of novel antibiotics,” Wockhardt MD Murtaza Khorakiwala said.
Wockhardt shares were trading up by 2.45 per cent at Rs 592.80 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.